Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24088686 | 1.00 | GAA (0.32) | GAAALDH1A1LMNA | |
| SCHEMBL23793983 | 1.00 | GAA (0.32) | GAAALDH1A1LMNA | |
| SCHEMBL22681237 | 1.00 | GAA (0.32) | GAAALDH1A1LMNA | |
| SCHEMBL22001985 | 0.85 | MAPK1 (0.35) | GAAALDH1A1 | |
| SCHEMBL20078987 | 0.82 | ALDH1A1 (0.32) | GAAALDH1A1LMNA | |
| SCHEMBL21420064 | 0.80 | LMNA (0.40) | GAAALDH1A1LMNA | |
| SCHEMBL21695109 | 0.80 | LMNA (0.40) | GAAALDH1A1LMNA | |
| SCHEMBL22710509 | 0.80 | LMNA (0.40) | GAAALDH1A1LMNA | |
| SCHEMBL20078920 | 0.78 | — | — | |
| SCHEMBL24878752 | 0.76 | ALDH1A1 (0.35) | GAAALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409619-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2022-12-29 | — | — | US | disclosed |
| US-20210403465-A1 | QUINAZOLINYL-INDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2021-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409619-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2E, POLR2H | GAA 278/4885ALDH1A1 2912/4885LMNA 3667/4885 |
| US-20210403465-A1 | QUINAZOLINYL-INDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, IRF3, MAVS | GAA 821/4885ALDH1A1 3358/4885LMNA 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.